You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The Afternoon Show in Gynecologic Oncology: PARP Inhibitors Across the Ovarian Cancer Disease Continuum

  • Authors: Ana Oaknin, MD, PhD
  • CME / ABIM MOC Released: 4/14/2022
  • Valid for credit through: 4/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, including gynecologic oncologists and obstetricians/gynecologists.

The goal of this activity is that learners will be better able to examine the current and future utility of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced ovarian cancer (OC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data from studies evaluating PARP inhibitors in advanced OC
    • Patient subsets most likely to benefit from PARP inhibitor therapies
  • Have greater competence related to
    • Selecting an appropriate PARP inhibitor for treatment of advanced OC
    • Implementing PARP inhibitors in the maintenance setting
  • Demonstrate greater confidence in their ability to
    • Identify patients eligible to receive PARP inhibitor therapy across the OC treatment continuum


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Ana Oaknin, MD, PhD

    Principal Investigator
    Gynecologic Malignancies Group
    Vall d'Hebron Institute of Oncology
    Head of Gynecologic Tumors Unit
    Full-Time Senior Medical Oncologist and Attending Physician
    Medical Oncology Department
    Vall d'Hebron University Hospital
    Barcelona, Spain

    Disclosures

    Consultant or advisor for: Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera Pharmaceutical; Eisai Europe Limited; EMD Serono Inc.; F. Hoffman-La Roche; GlaxoSmithKline; Immunogen; KL Logistics; Medison Pharma; Merck Sharp & Dohme de Espana; Mersana Therapeutics Inc.; Novocure GmbH; PharmaMar; prIME Oncology; Roche Farma; Sattucklabs; Sutro Biopharma, Inc.
    Research funding from: AbbVie Deutschland GmbH & Co Hg; Ability Pharmaceuticals; Advaxis Inc.; Agenus; Aprea Therapeutics AB; AstraZeneca AB; BeiGene USA Inc.; Bristol Myers Squibb International Corporation; Clovis Oncology; Corcept Therapeutics; Eisai; F. Hoffman-La Roche; Immunogen; Iovance Biotherapeutics; Lilly; Medimmune; Merck Healthcare; Merck Sharp & Dohme; Millennium Pharmaceuticals; Mundipharma Research; Novartis Farmaceutica; Regeneron Pharmaceuticals; Seagen Inc., formerly Seattle Genetics, Inc.; Sutro Biopharma; Tesaro; Verastem Oncology

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The Afternoon Show in Gynecologic Oncology: PARP Inhibitors Across the Ovarian Cancer Disease Continuum

Authors: Ana Oaknin, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 4/14/2022

Valid for credit through: 4/14/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to examine the current and future utility of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced ovarian cancer (OC).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print